Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis

Massachusetts Eye and Ear Infirmary

Overview

Juvenile onset recurrent respiratory papillomatosis (JORRP) is a rare, difficult to treat, benign tumor of the pediatric airway. Current therapy is mainly surgical, but in a significant portion of patients adjuvant therapy is required to control the disease process. Although multiple adjuvant medical therapies have been tried, success has been limited. We have seen some success in a limited amount of patients using orally administered propranolol. Our goal is to enroll a larger cohort of patients to determine the effectiveness of propranolol as an adjuvant therapy for JORRP.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Recurrent Respiratory Papillomatosis

Interventions

PropranololDRUG

Propranolol 2mg/kg divided twice daily

Eligibility

Sex: ALLMin age: 1 YearMax age: 10 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1\. Biopsy proven with appropriate Human Papilloma Virus typing Recurrent Respiratory Papilloma * 2\. Child under age 10 * 3\. Informed consent and where appropriate informed assent * 4\. Children who have undergone at least 4 documented surgical interventions in the past year. Exclusion Criteria: * Parental or child refusal to participate * Heart failure * Atrio-ventricular heart block * Cardiac anomalies * Low resting heart rate * Low resting blood pressure * Wolff-Parkinson White Syndrome * Unexplained syncope * Asthma or Reactive airway disease * Renal or liver failure * Expected long fasting periods, \>12 hours * Diabetes Mellitus * Hypersensitivity to propranolol

Outcomes

Primary Outcomes

Decreased number of surgeries

Time frame: 3 months

Secondary Outcomes

Improved voice quality

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.